Frost & Sullivan Independent Equity Research

RedHill Biopharma Ltd.: RedHill gives up migraine product (RHB-103). Upside remains, but the price target is decreased to NIS 2.27.

redhill

Company: RedHill Biopharma        

Sector: Pharmaceuticals

Report type: Update Report

Published on: December 13, 2017

RedHill research articles:

Close Menu
Font Resize